<DOC>
	<DOCNO>NCT00098163</DOCNO>
	<brief_summary>The purpose study test safety immune response HIV-1 vaccine , ALVAC-HIV vCP1521 , give infant bear HIV-1 infected mother Uganda .</brief_summary>
	<brief_title>Safety Immune Response HIV-1 Vaccine ( ALVAC-HIV vCP1521 ) Infants Born HIV Infected Mothers</brief_title>
	<detailed_description>Mother-to-child transmission ( MTCT ) HIV cause either perinatal transmission HIV breastfeeding , common practice poorer region world . HIV preventive vaccine currently investigation potential solution worldwide MTCT HIV . This study evaluate safety immunogenicity HIV-1 vaccine , ALVAC-HIV vCP1521 , infant bear HIV-1 infected mother Uganda . The vaccine preparation live attenuate recombinant canarypox virus , encode HIV clade B E envelope proteins . This study conduct Mulago Hospital Uganda . Mothers enroll study third trimester pregnancy . During screening , mother undergo medical history assessment , physical exam , blood collection . After delivery prior infant enrollment , mother another physical exam ; mother infant accompany home home visitor document contact information . Infants follow 24 month birth . Infants randomly assign receive 4 injection vaccine placebo . Study injection give start study Weeks 4 , 8 , 12 . Infants observe 1 hour vaccine administration check body temperature local systemic reaction . They also evaluate clinic day immunization local systemic reaction . Infants visit home 2 day vaccine administration train study nurse ass reactogenicity . Blood collect 9 select time : study entry , Weeks 2 , 6 , 10 , 14 , Months 6 , 12 , 18 , 24 . Sixteen study visit occur 2 year include medical history assessment physical exam . Childhood immunization give infant study entry Weeks 6 , 10 , 14 Months 6 12 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria HIV Infected Women : HIV infect In third trimester pregnancy CD4 count 500 cells/mm3 screen Intends give birth Mulago Hospital , Uganda Willing take home home visitor delivery document locator information willing visit home later Inclusion Criteria Infants Born HIV Infected Women : 3 few day age Born HIV infect woman eligible study Weight birth least 2000 g ( 4.4 lb ) Exclusion Criteria HIV Infected Women : Prior participation HIV1 vaccine trial Investigational agent , blood product , immunoglobulin , immunotherapy time pregnancy Documented suspect serious medical illness lifethreatening condition may interfere study Multiple birth predict current pregnancy Exclusion Criteria Infants Born HIV Infected Women : Mother leave study prior infant enrollment randomization Mother infant receive active passive HIV immunotherapy investigational product study vaccine . Mothers infant take nevirapine prior study entry exclude . Blood product , immunoglobulin , immunosuppressive therapy labor delivery prior study enrollment Abnormal vital sign prior vaccination clinical symptom may interfere vaccine reaction assessment Part multiple birth</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>HIV Seronegativity</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
</DOC>